Clinical Trials Logo

Filter by:
NCT ID: NCT00122681 Completed - Clinical trials for Infections, Papillomavirus

Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18

Start date: May 6, 2004
Phase: Phase 3
Study type: Interventional

Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the uterus or womb). This infection often goes away by itself, but if it does not go away (this is called persistent infection), it can lead in women over a long period of time to cancer of the cervix. If a woman is not infected by HPV, it is very unlikely that she will get cervical cancer. This study will evaluate the efficacy of GSK Biologicals HPV 16/18 VLP/AS04 vaccine to prevent infection associated cervical pre-cancer and vaccine with HPV 16 or 18 and the vaccine safety, over 48 months, in young adolescents and women of 15/25 years of age at study start. Approximately 18.000 study subjects will either receive the HPV vaccine or a control vaccine (hepatitis A vaccine) administered intramuscularly according to a 0-1-6 month schedule. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

NCT ID: NCT00122382 Completed - Clinical trials for Rheumatoid Arthritis

Remission and Joint Damage Progression in Early Rheumatoid Arthritis

Start date: July 2005
Phase: Phase 3
Study type: Interventional

This is a world wide study to evaluate the remission and joint damage in subjects treated with abatacept in addition to methotrexate versus subjects who receive methotrexate along with a placebo.

NCT ID: NCT00122356 Completed - Breast Cancer Clinical Trials

Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment

BATMAN
Start date: September 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the use of an oral bisphosphonate (alendronate) in preventing bone loss in postmenopausal women with early breast cancer who are receiving anastrozole therapy, and to determine how long alendronate treatment is needed.

NCT ID: NCT00122330 Completed - Clinical trials for Hemoglobinuria, Paroxysmal

Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

Start date: October 2004
Phase: Phase 3
Study type: Interventional

The primary objective is to evaluate the safety and efficacy of eculizumab in transfusion dependent patients with hemolytic PNH.

NCT ID: NCT00122317 Completed - Clinical trials for Paroxysmal Hemoglobinuria, Nocturnal

Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)

Start date: May 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the long-term safety of eculizumab in patients with transfusion dependent hemolytic PNH.

NCT ID: NCT00122304 Completed - Clinical trials for Hemoglobinuria, Paroxysmal

Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab

Start date: December 2004
Phase: Phase 3
Study type: Interventional

The primary objective is to evaluate the safety of eculizumab in patients with transfusion-dependent hemolytic PNH

NCT ID: NCT00121784 Terminated - Clinical trials for Heart Transplantation

Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients

Start date: October 2005
Phase: Phase 4
Study type: Interventional

Heart transplant patients on a standard care regimen of CNI, MMF, and corticosteroids will enter the study 4-6 weeks post-transplant. At 3 months after transplant, patients will be randomized to either continue this regimen or CNI therapy will be discontinued and replaced by sirolimus therapy (in combination with MMF and corticosteroids). The effect of these 2 regimens on efficacy, safety and renal function will be evaluated.The anticipated time on study treatment is 1-2 years and the target sample size is 500+ individuals.

NCT ID: NCT00121667 Completed - Clinical trials for Diabetes Mellitus, Type 2

Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone

Start date: August 2005
Phase: Phase 3
Study type: Interventional

The purpose of this clinical research study is to learn whether Saxagliptin added to Metformin therapy is more effective than Metformin alone as a treatment for type 2 diabetic subjects who are not sufficiently controlled with Metformin alone

NCT ID: NCT00121641 Completed - Clinical trials for Diabetes Mellitus, Type 2

Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Start date: July 2005
Phase: Phase 3
Study type: Interventional

The purpose of this clinical research study is to learn whether saxagliptin (BMS-477118) is more effective than placebo as a treatment for type 2 diabetic subjects who are not sufficiently controlled with diet and exercise

NCT ID: NCT00120601 Active, not recruiting - Alcoholism Clinical Trials

Trial for the Treatment of Alcohol Dependence

Start date: March 2003
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the effectiveness of two anti-craving medications, naltrexone versus acamprosate, in the treatment of alcohol dependence.